Danaher Corporation vs iShares JPMorgan USD Emerging Markets Bond ETF — how do they compare? Danaher Corporation trades at $219.24 (market cap $152.87B), while iShares JPMorgan USD Emerging Markets Bond ETF trades at $90.93 (market cap $12.87B). The key difference: Danaher Corporation is far larger — about 11.9× iShares JPMorgan USD Emerging Markets Bond ETF's market cap, and Danaher Corporation pays a 0.74% dividend while iShares JPMorgan USD Emerging Markets Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and iShares JPMorgan USD Emerging Markets Bond ETF for 50 Days on average.
| DHR | EMB | |
|---|---|---|
Market Cap | $152.87B | $12.87B |
Volume | 5,228,698 | 14,946,002 |
Sector | Health | Fixed Income |
52-Week High | $242.05 | $97.74 |
52-Week Low | $161.91 | $90.14 |
Typical Hold Time | 69 Days | 50 Days |
Enterprise Value | $175.08B | — |
Dividend Yield | 0.74% | — |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
EMB trades at $90.96 with minimal daily movement (+0.2%), showing technical bearish signals from moving averages while oscillators remain neutral. The stock faces resistance at $91-92 with support at $90. Recent dividend declarations of $0.41-0.44 per share provide income appeal, though key financial ratios remain undisclosed in current data.
The outlook appears cautious with technical indicators signaling bearish momentum. Income-focused investors may find value in the dividend yield, but limited fundamental data availability and bearish technical signals suggest careful evaluation is warranted. Market risks include broader economic pressures affecting bond yields and emerging market exposure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →